Cytokinetics
Price
Price
CHART BY
Frequently asked questions
What is Cytokinetics's market capitalization?
What is the Earnings Per Share (EPS) for Cytokinetics?
What are the analyst ratings and target price for Cytokinetics's stock?
What is Cytokinetics's revenue over the trailing twelve months?
What is the EBITDA for Cytokinetics?
What is the free cash flow of Cytokinetics?
How many employees does Cytokinetics have, and what sector and industry does it belong to?
What is the free float of Cytokinetics's shares?
Financials
- Market Cap
- $5.77B
- EPS (TTM)
- -$5.389
- Free Float
- 113.56M
- Revenue (TTM)
- $3.22M
- EBITDA (TTM)
- -$511.14M
- Free Cashflow (TTM)
- -$407.05M
Pricing
- 1D span
- $48.94$49.26
- 52W span
- $43.58$110.00
Analyst Ratings
The price target is $80.94 and the stock is covered by 17 analysts.
Buy
13
Hold
4
Sell
0
Information
Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Its clinical-stage drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator, CK-136, a novel cardiac troponin activator, reldesemtiv, a novel fast skeletal muscle troponin activator, aficamten, a novel cardiac myosin inhibitor, and CK-3772271, a novel cardiac myosin inhibitor. The company was founded by Ronald D. Vale, Lawrence S. B. Goldstein, James H. Sabry, and James A. Spudich in 1997 and is headquartered in South San Francisco, CA.
- Employees
- 423
- Industries
- Pharmaceuticals: Major
- Sector
- Health Care
Identifier
- ISIN
- US23282W6057
- Primary Ticker
- CYTK